CPHI

CPHI is a $29M Nevada shell operating entirely through Hainan Helpson in the PRC, and the numbers describe a business in structural decline, not a turnaround. Revenue has fallen every year for four straight years — from $9.64M (FY2021) to $4.14M (FY2025), a -8.5% drop in the latest year alone — while the company has posted a net loss every single year over that span (-$3.4M, -$3.97M, -$3.08M, -$4.74M, -$3.19M). The most damning line is gross profit: it is *negative* at -$132K, a -3.2% gross margin, meaning Helpson sells its drugs for less than they cost to make before a dollar of overhead. Operating margin is -78% and net margin -77%. This is not a scaling problem you grow out of; the unit economics are broken.

The MD&A explains why, and it is not fixable on management's terms. China's Centralized Procurement (CP) regime has run nine bidding rounds that 'significantly reduced the price of the drugs that won the bids,' and CP eligibility now requires passing the Consistency Evaluation — which management admits it is making 'slow progress' on and has taken a 'more cautious and flexible attitude' toward, i.e. is largely declining to fund. The risk factors confirm most products are 'off-patent branded generics' that anyone can copy. So the company is caught between generic price competition and a state procurement system it can't afford to qualify for, which is exactly what the four-year revenue slide shows.